Anabel Sorolla Bardaji
Grau: Doctor/a
asorolla(ELIMINAR)@irblleida.cat
ResearcherID: http://www.researcherid.com/rid/E-2546-2012
Publicacions
-
Golden E; Rashwan R; Woodward EA; Sgro A; Wang E; Sorolla A; Waryah C; Tie WJ; Cuyàs E; Ratajska M; Kardas I; Kozlowski P; Johnstone EKM; See HB; Duffy C; Parry J; Lagerborg KA; Czapiewski P; Menendez JA; Gorczynski A; Wasag B; Pfleger KDG; Curtis C; Lee BK; Kim J; Cursons J; Pavlos NJ; Biernat W; Jain M; Woo AJ; Redfern A; Blancafort P
The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.
Nature Communications 12 1920-1920. .
-
Parisi E; Sorolla A; Montal R; González-Resina R; Novell A; Salud A; Sorolla MA
Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis.
Cancers 12 1-28. .
-
Sorolla, A; Sorolla, MA; Wang, E; Ceña V
Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment.
Expert Opinion on Drug Delivery 17 1-17. .
-
Wang E; Sorolla A
Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition.
Journal of Gynecologic Oncology 31 -. .
-
Wang, E; Sorolla, MA; Krishnan PDG; Sorolla, A
From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.
Biomolecules 10 -. .
-
Sorolla A; Wang E; Golden E; Duffy C; Henriques ST; Redfern AD; Blancafort P
Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.
ONCOGENE 39 1167-1184. .
-
Duffy C; Sorolla A; Wang E; Golden E; Woodward E; Davern K; Ho D; Johnstone E; Pfleger K; Redfern A; Iyer KS; Baer B; Blancafort P
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer.
npj Precision Oncology 4 24-24. .
-
Kretzmann JA; Evans CW; Moses C; Sorolla A; Kretzmann AL; Wang E; Ho D; Hackett MJ; Dessauvagie BF; Smith NM; Redfern AD; Waryah C; Norret M; Iyer KS; Blancafort P
Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers.
Chemical Science 10 7718-7727. .
-
Sorolla A; Wang E; Clemons TD; Evans CW; Plani-Lam JH; Golden E; Dessauvagie B; Redfern AD; Swaminathan-Iyer K; Blancafort P
Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.
Nanomedicine-Nanotechnology Biology and Medicine 20 102003-102003. .
-
Wang E; Sorolla A; Cunningham PT; Bogdawa HM; Beck S; Golden E; Dewhurst RE; Florez L; Cruickshank MN; Hoffmann K; Hopkins RM; Kim J; Woo AJ; Watt PM; Blancafort P
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
ONCOGENE 38 140-150. .
-
Clemons TD; Singh R; Sorolla A; Chaudhari N; Hubbard A; Iyer KS
Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy.
LANGMUIR 34 15343-15349. .
-
Shrestha S; Sorolla A; Fromont J; Blancafort P; Flematti GR
Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells.
Marine Drugs 16 -. .
Projectes
- DEVELOPMENT OF PRECISION THERAPIES FOR TRIPLE NEGATIVE BREAST CANCERS BASED ON CRISPR/CAS9 RIBONUCLEOPROTEINS.
- Ajuts contractació personal investigador predoctoral en formació (FI2022)
- Development of precision therapies for triple negative breast cancer based on CRISPR/Cas12a ribonucleoproteins
- Contrato Miguel Servet - Proyecto + RRHH
- EXPRESION DE CANALES DE CALCIO DE TIPO T EN NEOPLASIAS MELANOCÍTICAS BENIGNAS Y MALIGNAS. EVALUACION DE SU APLICICABILIDAD CLINICA COMO DIANAS TERAPEUTICAS EN EL MELANOMA
